Amino Acids as biomarkers in the SOD1G93A mouse model of ALS  by Bame, Monica et al.
Biochimica et Biophysica Acta 1842 (2014) 79–87
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbad isAmino Acids as biomarkers in the SOD1G93A mouse model of ALSMonica Bame, Robert E. Grier 1, Richard Needleman, William S.A. Brusilow ⁎
Department of Biochemistry and Molecular Biology, Wayne State University School of Medicine, 540 E. Canﬁeld Street, Detroit, MI 48230, USA⁎ Corresponding author.
E-mail address: wbrusilo@med.wayne.edu (W.S.A. Bru
1 Department of Pathology, Wayne State University S
University Hospital.
0925-4439/$ – see front matter © 2013 Elsevier B.V. All r
http://dx.doi.org/10.1016/j.bbadis.2013.10.004a b s t r a c ta r t i c l e i n f oArticle history:
Received 22 August 2013
Received in revised form 26 September 2013
Accepted 7 October 2013





MethylationThe development of therapies for Amyotrophic Lateral Sclerosis (ALS) has been hindered by the lack of
biomarkers for both identifying early disease and for monitoring the effectiveness of drugs. The identiﬁcation
of ALS biomarkers in presymptomatic individuals might also provide clues to the earliest biochemical correlates
of the disease. Previous attempts to use plasma metabolites as biomarkers have led to contradictory results,
presumably because of heterogeneity in both the underlying genetics and the disease stage in the clinical
population. To eliminate these two sources of heterogeneity we have characterized plasma amino acids and
other metabolites in the SOD1G93A transgenic mouse model for ALS. Presymptomatic SOD1G93A mice have
signiﬁcant differences in concentrations of several plasma metabolites compared to wild type animals, most
notably in the concentrations of aspartate, cystine/cysteine, andphosphoethanolamine, and in changes indicative
of methylation defects. There are signiﬁcant changes in amino acid compositions between 50 and 70days of age
in both the SOD1G93A and wild type mice, and several of the age-related and disease-related differences in
metabolite concentration were also gender-speciﬁc. Many of the SOD1G93A-related differences could be altered
by treatment of mice with methionine sulfoximine, which extends the lifespan of this mouse, inhibits glutamine
synthetase, and modiﬁes brain methylation reactions. These studies show that assaying plasma metabolites can
effectively distinguish transgenicmice fromwild type, suggesting that one ormore plasmametabolitesmight be
useful biomarkers for the disease in humans, especially if genetic and longitudinal analysis is used to reduce
population heterogeneity.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
The intense efforts made in unraveling the genetic and neurological
bases of amyotrophic lateral sclerosis (ALS) have not led to the
discovery of drugs that can substantially change the progress of the
disease: fasciculations, muscle weakness and atrophy, and death from
respiratory failure within 3–5 years of diagnosis. No effective therapy
exists, and a deﬁnitive diagnosis can only be made after signiﬁcant
neuronal damage has already occurred [1].
Drug development has relied heavily on a mouse model in which
genomic insertion of multiple copies of the human mutant SOD1 gene,
most often SOD1G93A, causes a disease very similar to ALS. Most of the
drugs found to be useful in increasing survival in the ALS mouse
model have failed clinical trials [2]. Many reasons can be postulated
for this failure: obvious differences between the disease in mice and
humans (e.g., cause of death), the difﬁculty of conducting dose response
studies in a sufﬁciently large population of patients having a relatively
rare disease, and most importantly the absence of biological markers
of disease progression that would increase the statistical power ofsilow).
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patients at different disease stages and whose underlying genetics
may reﬂect different biochemical abnormalities. ALS patients with
SOD1 mutations represent only about 5% of familiar cases and would
thus be underrepresented in clinical trials [1,3].
Successful drug discovery is greatly facilitated by the identiﬁcation
of appropriate biomarkers, deﬁned as an ‘objective measurement
that acts as an indicator of normal biological processes, pathogenic
processes, or pharmacological response to therapeutic intervention’
[4]. In addition to serving as a surrogate marker in drug studies, such
biomarkers can establish the underlying biochemistry of ALS, and lead
to early diagnosis and the identiﬁcation of drug targets. The identi-
ﬁcation of biomarkers in ALS has been a very active area of investigation,
employing transcriptional studies, protein proﬁling in blood and CSF,
imaging, and electrophysiological techniques [5]. While these tech-
niques have identiﬁed some potential ALS biomarkers, so far none
have proven to be clinically useful.
The ideal biomarker for drug development is one for which there is
an inexpensive and minimally invasive assay that can be done in the
usual hospital setting. Plasma amino acid concentrations satisfy these
criteria. Although the proximate cause of death in ALS is the destruction
of motor neurons, ALS is a multi-organ disease that also affects the liver
and skeletal muscle, two organs which are central participants in
determining plasma amino acid concentrations [6,7]. In several studies
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to be of clinical value in either disease diagnosis or as a measure
of disease progression. While statistically signiﬁcant differences
between unaffected and ALS patients have been found, the amino acid
biomarkers identiﬁed have varied from study to study and have
produced no consistent pattern of disease-related differences. In one
study tyrosine, valine, methionine, leucine, and isoleucine were
found to be reduced in ALS and increases in glutamine and serine;
another study showed increases in threonine, glutamate and cystine,
and reductions in phenylalanine and histidine; a third report found
only decreases in alanine, isoleucine, methionine, leucine and tyrosine
[8–10].
We reevaluate here the use of amino acids as biomarkers in the
SOD1G93A mouse, thus eliminating several sources of heterogeneity
found in clinical studies. In this mouse model the disease proceeds in
a highly uniform way with motor symptoms appearing at around
70 days and death occurring at around 125 days. As a result, in the
asymptomatic SOD1G93A mouse we are able to identify amino acid
biomarkers both of ALS and of disease progression.
Methionine sulfoximine (MSO), a drug which inhibits a central
enzyme in amino acid metabolism, glutamine synthetase, and which
we have found to increase survival (especially in females), also
normalizes some of the amino acid abnormalities, and does so in a
gender-speciﬁc manner [11]. Furthermore, some of the differences
seen in amino acid proﬁles of SOD1G93A mice are gender-speciﬁc, with
males and females showing different metabolic proﬁles; the proﬁles
also differ by the disease stage.
Our results suggest that plasma analysis of certain amino acids may
prove to be an effective tool in clinical studies on humans, if such
biomarkers can also be identiﬁed in patients. Previous studies present
results from analysis of a single plasma sample, but repeatedly sampling
patients during the disease process will signiﬁcantly reduce biological
variability, allowing the identiﬁcation of a “biochemical or metabolic”
classiﬁcation of changing plasma amino acid proﬁles during the normal
disease process. Used in conjunction with the identiﬁcation of the
particular gene affected in each FALS (Familial Amyotrophic Lateral
Sclerosis) patient, this approach may allow the use of plasma amino
acid analysis as a biomarker for ALS.
2. Materials and methods
2.1. Animal breeding and care
All animal experiments were approved byWayne State University's
Animal Investigation Committee. SOD1G93A breeding mice were
obtained from Jackson Laboratories. Female C57BL/6*SJL mice were
crossed with B6SJL males over expressing the human SOD1 transgene
containing the G93A mutation (SOD1G93A).
2.2. Experimental groups
The 50 day group consisted of untreated wild-type and SOD1G93A
mice from which liver, central nervous system tissue and plasma were
collected at 50 ± 2 days of age. The 70 day group consisted of wild-
type and SOD1G93A mice that were given weekly i.p. injections of saline
or 20 mg/kg body weight MSO (Sigma Chemical Company, no. 5379)
starting at 50 ± 2 days of age and were euthanized at 70 ± 2 days of
age. Mice were euthanized and plasma collected for analysis within
1–3days after the ﬁnal injection.
2.3. Plasma and tissue collection
Mice were anesthetized with an i.p. injection of Avertin (0.4–0.75mg/g
body weight) and blood was collected via cardiac puncture. Blood was
placed in BDMicrotainer tubes containing lithium heparin and centrifuged
at 16,000×g for 3min in a Sorvall Biofuge pico desktop centrifuge to obtainplasma. For all animals, 100μL aliquots of plasmawere taken for plasma
ammonia analysis and the remaining plasma was immediately frozen
on dry ice for later use. All tissue samples were placed in centrifuge
tubes and immediately frozen on dry ice and thawed prior to
homogenization.
2.4. Plasma ammonia determination
Plasma ammonia levels were determined using the Berthelot
indophenol reaction as described by Brusilow [12]. Ammonia levels
were determined by comparing sample absorbances to those of an
ammonium sulfate standard curve and values were expressed as μmol
of ammonia per liter of plasma.
2.5. Plasma amino acid analysis
Plasma samples that were not used for ammonia determination
were immediately frozen on dry ice. They were analyzed for plasma
metabolites using a BioChrom 30+ Amino Acid Analyzer in the
Biochemical Genetics Laboratory in the Detroit Medical Center. The
plasma samples were deproteinized with 5-sulfosalicylic acid (SSA).
12 μg SSA was added to 350 μl of plasma, and after 5 min on ice, the
precipitate was spun down, and the supernatant fraction was ﬁltered
and treated with 200mM DTT for an hour at 37 °C, which converts all
the cystine in the plasma to cysteine for analysis. Reported levels of
cysteine therefore represent plasma cystine plus cysteine.
2.6. Glutamine synthetase activity assays
Brain preparations for GS activity were carried out as described by
Meister [13]. Liver sample preparation was carried out using a modiﬁed
version of Pierson's protocol for preparation of samples for CPSI activity
assays [14]. GS activity was determined using a modiﬁed version of
the gamma-glutamyltransferase reaction described by Meister [13].
The reaction was carried out for 10 min at 37 °C in the presence of
100 mM L-glutamine. Sample absorbances were read at a wavelength
of 535 nm, and the extinction coefﬁcient of the product, glutamyl
hydroxamate, is reported to be .850M−1 cm−1 [15]. Ovariectomization
was performed on 30–40 day-old females, before the animals had
reached sexual maturity, and were carried out as described previously
[16].
GS activity assays were performed on brain and liver homogenates
from ovariectomized and intact 70-day female mice. Absorbance values
were converted tomicromoles of product formedby comparing them to
an L-γ-glutamyl hydroxamate standard curve and speciﬁc activities
were determined accordingly.
2.7. Glutaminase activity assays
Glutaminase activity assays were carried out on the same brain
homogenates used for GS activity assays. Brain glutaminase activity
was determined by monitoring the production of ammonia using a
modiﬁed version of Sigma's protocol for the enzymatic assay of
glutaminase from E. coli. Test tubes containing 0.9 mL of glutaminase
reaction buffer (100 mM sodium phosphate, and 20 mM L-glutamine,
pH 8.0) were equilibrated to 37 °C in a water bath and 100 μL of brain
homogenate was added. The reaction was allowed to proceed for
15 min at 37 °C before being quenched with 9 mL of cold deionized
water on ice. A 100 μL aliquot from the quenched reaction mixture
was added to a tube containing 200 μL of deionized water and 50 μL of
the prepared ion-exchange resin used for determining ammonia levels.
The ammonia assay was then carried out from this point to determine
the amount of ammonia produced during the reaction. Ammonia
produced during the reaction was quantiﬁed by reading absorbances
of samples at 630 nm and comparing them to absorbance values from
an ammonium sulfate standard curve. Glutaminase activity assays
81M. Bame et al. / Biochimica et Biophysica Acta 1842 (2014) 79–87were performed on 5–8 brain samples per treatment group for each
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2.8. Carbamoyl phosphate synthase I activity assays
Sample preparation and carbamoyl phosphate synthetase I enzymatic
activity assays were carried out according to a modiﬁed version of a
protocol by Pierson [14]
3. Results
Death occurs in SOD1G93A mice at around 125 days of age with
muscle weakness appearing at about 90 days. We collected plasma
and measured amino acid levels in asymptomatic SOD1G93A and
congenic wild type mice at 50 and 70days of age.
3.1. Plasma amino acid proﬁles differ between asymptomatic SOD1G93A
mice and congenic wild type mice
Table 1 shows those plasma amino acids and other metabolites that
differ statistically (pb0.05) between asymptomatic SOD1G93A mice and
congenic wild type mice, pooling the data for both 50 and 70-day time
points. In cases where the distribution was severely non-normal as
shown by the Shapiro–Wilk test, the nonparametric Mann–Whitney
test for signiﬁcance was used, as indicated.
The cutoff two-sided p valuewas pb0.05 for both tests, but since low
p values do not reﬂect the magnitude of statistical differences, we also
used a standard measure of effect size, Cohen's d statistic, to identify
the most important differences [17]. The test provides a measure of
the overlap of the distribution in standard deviation units of amino
acid concentrations between wild type and SOD1G93A mice. For
example, if d = 0.8 then the mean for SOD1G93A mice is at the 79th
percentile of the value obtained for the wild type mice; if d=1.0, the
84th percentile; if d = 2.0, the 97.7th percentile. The standard
interpretation of effect sizes is to identify d N 0.8 as a ‘large effect’ and
0.5 b d b 0.8 as a ‘medium effect’. Large effect sizes are found for
phosphoserine (Phser), phosphoethanolamine (Pea), aspartate (Asp),
citrulline (Citr), cysteine (Cys), and arginine (Arg); moderate effect
sizes are found for glutamine (Gln), glutamate (Glu), ornithine (Orn),
sarcosine (N-methylglycine) (Sarc), and methionine (Met). We include
serine (Ser), which approaches our pb0.05 cutoff, since it is relevant to
our later discussion of the phosphoserine pathway. The 95% conﬁdenceTable 1
Comparison of the average metabolite levels of all untreated and saline-treated wild-type
mice to those of all untreated and saline-treated SOD1G93A mice, irrespective of age. All
values are expressed as averages in μmol/L (SEM). For the plasma ammonia analysis
n = 57 wild-type (WT) mice and n = 55 SOD1G93A mice (*). For the remainder of the
plasma metabolites n = 31 wild-type mice and n = 27 SOD1G93A mice. In cases where
data were non-normally distributed the Mann–Whitney test for signiﬁcance was used to
determine p values (†). Normal three-letter abbreviations for amino acids were used, in






p d (95% CI)
Ammonia * 45 (4) 58 (5) 0.05 0.4 (0.0–0.7)
Arg 117 (6) 94 (5) 0.01 0.8 (0.2–1.3)
Asp 16.1 (1.1) 10.2 (0.5) 0.00 1.2 (0.7–1.8)
Citr 103 (4) 84 (3) 0.00 1.0 (0.4–1.5)
Cys 22 (3) 0.2 (0.9) 0.00 † 2.0 (1.4–2.6)
Gln 570 (13) 634 (23) 0.02 0.7 (0.1–1.2)
Glu 27 (4) 18 (2.6) 0.04 0.6 (0.0–1.1)
Met 92 (6) 74 (5) 0.03 0.6 (0.08–1.1)
Orn 90 (6) 73 (5) 0.04 0.6 (0.05–1.1)
Pea 9.4 (1.1) 3.2 (1.1) 0.00 1.0 (0.5–1.6)
Phser 12.6 (1.2) 6.4 (0.8) 0.00 1.1 (0.6–1.7)
Sarc 9.3 (3.1) 23 (4) 0.01 † 0.7 (0.2–1.2)
Ser 155 (5) 142 (4) 0.06 0.5 (0.0–1.0)intervals on d are large, so a conservative measure is to use the
minimum value to identify themost reliablemajor differences: cysteine
(1.4), aspartate (0.7), and phosphoserine (0.6). Of course, this
restriction does not exclude the other amino acidswith smaller d values
as being useful diagnostic markers.
3.2. The amino acid proﬁle can identify presymptomatic SOD1G93A mice
If a disease-related difference has a large Cohen effect size, it implies
that there is low overlap between the amino acid concentrations in the
two populations; in other words, the larger the d, the more likely that
the plasma concentration of that amino acid can correctly assign a
mouse to the correct group. We therefore further analyzed the
concentrations of cysteine, aspartate, phosphoserine, citrulline, and
phosphoethanolamine to attempt to predict the mouse genotype.
A logistic regression analysis using cysteine, aspartate, phosphoserine,
citrulline and phosphoethanolamine correctly classiﬁes 26 of 31 (84%)
wild type and 26 of 27 (96%) SOD1G93Amice, essentially the same as
using only cysteine (81% wild type and 96% SOD1G93A). Conducting the
same regression analysis using just aspartate correctly classiﬁes 71% of
the wild type and 82% of the SOD1G93A mice; regression with just
phosphoethanolamine correctly classiﬁes 74% of the wild type and 70%
of the SOD1G93A mice.
A Receiver Operating Characteristic (ROC) analysis is commonly
used to evaluate the tradeoffs between test sensitivity (true positives)
and test speciﬁcity (false positives). The larger the area under the
curve (AUC), the better the diagnostic strength of the test, with
the maximum area possible equal to 1. The AUC for cysteine,
phosphoethanolamine, and aspartate is 0.9, 0.8, and 0.8 respectively.
So these amino acids can be conﬁdently used for a robust identiﬁcation
of presymptomatic SOD1G93A mice.
3.3. The amino acid proﬁle changes between 50 and 70days of age in both
wild type and SOD1G93A mice
The amino acid proﬁles of both wild type and SOD1G93A mice change
between the ages of 50 and 70days (Tables 2A and 2B). Wild-type mice
show signiﬁcant increases in average plasma levels of alanine,
asparagine, valine, isoleucine, leucine, phenylalanine, and proline while
SOD1G93A mice show signiﬁcant increases in average plasma levels of
urea and sarcosine with age. Changes common to both genotypes areTable 2A
Age-related changes in average plasma metabolite levels of wild-type mice. All values are
expressed as averages in μmol/L (SEM). For the plasma ammonia analysis n= 31 50-day
old wild-type (WT) mice and n = 27 70-day old wild-type mice (*). For the remainder
of the plasma metabolites n = 19 50-day old wild-type mice and n = 12 70-day old
wild-type mice. Normal three-letter abbreviations for amino acids were used, in addition
to AAAA (α-aminoadipic acid), Citr (citrulline), Pea (phosphoethanolamine), Phser
(Phosphoserine), and Taur (Taurine).




p d (95% CI)
Ammonia 52 (5) 27 (3) 0.00 1.1(0.5–1.7)
AAAA 26 (3) 14.7 (2.8) 0.02 0.9 (0.2–1.7)
Ala 578 (24) 675(29) 0.02 1.0 (0.2–1.7)
Asn 39 (2) 50 (5) 0.03 0.9 (0.1–1.6)
Asp 18.0 (1.5) 13.1 (1.4) 0.03 0.8 (0.1–1.6)
Citr 109 (5) 92 (7) 0.04 0.8 (0.2–1.5)
Cys 28 (2) 13.3 (6) 0.01 1.0 (0.2–1.7)
Glu 35 (4) 14.9 (3.6) 0.00 1.2 (0.5–2.0)
Ile 87 (4) 110 (9) 0.01 1.0 (0.3–1.8)
Leu 145 (5) 186 (15) 0.01 1.2 (0.4–2.0)
Pea 11.5 (1.3) 6.1 (1.7) 0.02 0.9 (0.2–1.7)
Phe 60 (2) 73 (5) 0.01 1.1 (0.4–1.9)
Phser 14.4 (0.8) 9.6 (2.7) 0.05 0.8 (0.03–1.5)
Pro 89 (4) 117 (10) 0.01 1.1 (0.4–1.9)
Taur 464 (33) 328 (20) 0.01 1.2 (0.4–1.9)
Val 247 (8) 312 (25) 0.01 1.1 (0.4–1.9)
Table 2B
Age-related changes in average plasma metabolite levels of SOD1G93A mice. All values are
expressed as averages in units of μmol/L (SEM). For the plasma ammonia analysis n=31
50-day old SOD1G93Amice and n=34 70-day old SOD1G93A mice (*). For the remainder of
the plasmametabolites n=13 50-day old SOD1G93Amice andn=14 70-day old SOD1G93A
mice. Normal three-letter abbreviations for amino acids were used, in addition to AAAA
(α-aminoadipic acid), Pea (phosphoethanolamine), Taur (Taurine), and Sarc (sarcosine).




p d (95% CI)
Ammonia 78(7.5) 35(3) 0.00 1.4(0.9–2.0)
AAAA 21 (4) 10.6 (1.4) 0.01 1.1 (0.3–1.9)
Asp 11.3 (0.9) 9.1 (0.3) 0.03 1.0 (0.2–1.8)
Glu 26 (3) 10.3 (3.2) 0.00 1.5 (0.7–2.4)
Pea 5.0 (2.1) 0(0) 0.03 1.0 (0.2–1.8)
Sarc 11.8 (5.3) 32 (5) 0.01 1.1 (0.3–1.9)
Taur 429 (37) 320 (26) 0.02 1.0 (0.2–1.8)
Urea 8089 (697) 10527 (433) 0.01 1.2 (0.4–2.0)
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adipic acid (AAAA), and glutamate.
Wild type and SOD1G93Amice therefore undergo different metabolic
programs as reﬂected in their plasma amino acid proﬁles during this
asymptomatic period.
3.4. At both 50 and 70 days wild type and SOD1G93A mice have different
plasma amino acid proﬁles
Table 3 compares amino acid proﬁles of wild-type and SOD1G93A
mice at 50 and 70 days of age. 50 day old SOD1G93A mice have higher
plasma ammonia levels and urea levels than wild type mice of the
same age. In addition, SOD1G93A mice have higher levels of glutamine
(the precursor of glutamate and ammonia), and lower levels of several
intermediates of the urea cycle – aspartate, citrulline, and arginine.
Remarkably, cysteine levels are extremely low in SOD1G93A mice when
compared to the wild type, with cysteine undetectable in the plasma
of all but one SOD1G93A mouse.
There are fewer signiﬁcant differences between saline-treated
SOD1G93A and wild-type mice at 70 days of age than at 50 days of age.
Ammonia is higher (because of a signiﬁcant difference in malesTable 3
Average concentrations of plasma metabolites of 50 and 70 day old wild-type and
SOD1G93A mice. All values are expressed as averages in μmol/L (SEM), and 70-day old
animals had been injected with saline once per week starting at 50 days of age. For the
plasma ammonia analysis of 50-day old animals n = 31 wild-type (WT) and 31
SOD1G93A untreated mice, and for 70-day old animals n = 27 wild-type and 34
SOD1G93A saline treated mice. For the remainder of the plasma metabolites n= 19 wild-
type and 13 SOD1G93A 50-day old untreated mice and n = 12 wild-type and 14
SOD1G93A 70-day old saline treated mice. In cases where the data were non-normally
distributed the Mann–Whitney test for signiﬁcance was used to determine p values (†).
Abbreviations are as described in Tables 1–2B.













Ammonia 52 (5) 78 (8) 0.02 27 (3) 35 (3) 0.07
Ala 578 (24) 673 (44) 0.04 675(29) 594 (33) 0.08
Arg 122 (8) 87 (8) 0.01 109 (8) 101 (8) 0.5
Asn 39 (2) 48 (4) 0.04 51 (5) 43 (3) 0.2
Asp 18.0 (1.5) 11.3 (0.9) 0.00 13.1 (1.4) 9.2 (0.4) 0.01
Citr 109 (5) 87 (6) 0.01 92 (7) 81 (4) 0.2
Cys 28 (2) 0.4 (0.4) 0.00 † 13.3 (5.5) 0.0 (0.0) 0.03 †
Gln 560 (13) 677 (37) 0.00 585 (27) 594 (24) 0.8
Gly 299 (7) 285 (13) 0.3 314 (12) 266(12) 0.00
Lys 320 (13) 274 (16) 0.03 290 (18) 280 (19) 0.7
Met 87 (6) 65 (7) 0.02 98 (12) 82 (7) 0.2
Pea 11.5 (1.3) 5.0 (2.0) 0.01 4.9(3.3) 0(0) 0.03 †
Phser 14.4 (0.8) 6.8 (1.2) 0.00 9.6 (2.7) 6.0 (1.0) 0.2
Sarc 11.9 (4.4) 11.8 (5.3) 1.0 4.9(3.3) 32 (5) 0.00
Urea 9867 (358) 8089 (697) 0.02 10640 (460) 10530 (430) 0.9although not in females (gender data shown below in Table 7),
phosphoethanolamine and aspartate are signiﬁcantly lower, and
cysteine was low or undetectable at both ages of SOD1G93A mice.
Lower glycine and higher sarcosine in SOD1G93A mice only become
apparent at 70days.
The combined 50 day and 70 day results (Table 1) identiﬁed 12
metabolites that are different in wild type and SOD1G93A animals:
phosphoserine, phosphoethanolamine, ammonia, aspartate, glutamine,
glutamate, sarcosine, citrulline, cysteine, ornithine, methionine, and
arginine. Only three of these, phosphoethanolamine, aspartate, and
cysteine, remain signiﬁcantly different between wild type and
SOD1G93A mice at 70 days of age (Table 3). But the older mice also
show differences in sarcosine and glycine that are absent in younger
mice.
3.5. Ovariectomization alters the plasma amino acid proﬁle and enzymes
involved in glutamine metabolism in SOD1G93A mice
Signiﬁcant gender differences in metabolites and clinical features
have been observed both in patients and in animal studies of ALS
[18–20]. We have previously shown that female SOD1G93A mice have
delayed neuromuscular degeneration compared to male SOD1G93A
mice [21]. Methionine sulfoximine (MSO), a potent inhibitor of a central
enzyme of nitrogen metabolism, glutamine synthetase, improves the
survival of both males and females, but with a much larger effect on
females [11,16]. Ovariectomization or castration eliminates the effect
of MSO on both neuromuscular degeneration and survival, consistent
with the view that estrogen is protective in ALS [16,22], and one aspect
of that protection involves an MSO-sensitive pathway. Because of these
results with MSO, and the disease-dependent alterations in ammonia
and metabolites involved in the urea cycle (arginine, ornithine,
citrulline, aspartate), we studied the effects of ovariectomization on
metabolites and enzymes involved in central processes of nitrogen
metabolism, in order to better deﬁne estrogen-dependent pathways
that might be involved in the disease process.
We ovariectomized mice between 30 and 40 days of age, before
maturity, then, at 70 days of age, we measured the activity of three
enzymes involved in nitrogen metabolism: glutamine synthetase levels
in the liver and brain, glutaminase in the brain, and carbamoyl
phosphate synthetase I (CPSI), the rate limiting enzyme of the urea
cycle, in liver at 70 days of age in intact and ovariectomized SOD1G93A
mice (Table 4). Ovariectomized SOD1G93A females have signiﬁcantly
lower levels of brain and liver glutamine synthetase (p = 0.04 and
p = 0.003 respectively), lower liver CPSI (p = 0.05), and elevated
brain glutaminase activity (p = 0.002). Thus the speciﬁc activities of
two enzymes involved in incorporation of ammonia into organic
molecules are lowered by ovariectomization, and an enzyme involved
in the production of ammonia is elevated by ovariectomization,
demonstrating an effect of sex hormones on ammonia metabolism in
these mice.
Ovariectomization also altered the amino acid proﬁle in SOD1G93A
mice (Table 5). Aspartate, proline, and α-aminoadipic acid levels areTable 4
The effects of ovariectomization on enzyme activity in female SOD1G93A mice. All speciﬁc
activities are expressed as averages of nmol product/minute/mg protein (SEM). n = 8
non-ovariectomized (OVR) and n= 7 ovariectomized female SOD1G93A mice (‡). n= 10
non-ovariectomized and n=9 ovariectomized female SOD1G93A mice (†). Abbreviations:








GS (brain) ‡ 1345 (97) 1099 (29) 0.04
Glutaminase (brain) ‡ 56 (7) 99 (8) 0.002
GS (liver) † 814 (26) 695 (21) 0.003
CPSI (liver) † 252 (11) 213 (14) 0.05
Table 5
The effects of ovariectomization on average plasmametabolite levels of 70-day old female
SOD1G93A mice. All values are expressed as averages in μmol/L (SEM). For the plasma
metabolite analysis n = 12 wild-type females, n = 12 non-ovariectomized SOD1G93A
females, and n= 10 ovariectomized SOD1G93A females. For the remainder of the plasma
metabolites n = 6 wild-type females, n = 7 non-ovariectomized SOD1G93A females, and
n = 11 ovariectomized SOD1G93A females. p values were obtained from the analysis
comparing non-ovariectomized SOD1G93A female mice to ovariectomized SOD1G93A









Ammonia 33 (5) 33 (4) 41 (4) 0.2
AAAA 16.1 (5.4) 11.2 (32.7) 19.6 (1.4) 0.006
Asp 13.3 (2.4) 9.2 (0.6) 4.6 (1.7) 0.04
His 82 (3) 82 (7) 63 (3) 0.01
Lys 318 (33) 318 (18) 250 (16) 0.01
Pro 121 (20) 70 (19) 113 (7) 0.02
Sarc 8.9 (5.6) 38 (5) 0.0 (0.0) 0.00
Ser 174 (19) 152 (6) 121 (6) 0.003
Thr 204 (30) 190 (11) 154 (11) 0.06
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threonine, serine, sarcosine, lysine, and histidine are all signiﬁcantly
lower in ovariectomized SOD1G93A females.Table 7
The effects of MSO treatment according to genotype and gender. All values are expressed
as averages in μmol/L (SEM). For the plasma ammonia analysis n = 12 mice/gender/
treatment. For the remainder of the plasma metabolites n values are as follows: 6 wild-
type males and 6 wild-type females treated with saline, 7 SOD1G93A males and 7
SOD1G93A females treated with saline, 8 SOD1G93A males and 8 SOD1G93A females treated
with MSO, and 5 wild-type males and 5 wild-type females treated with MSO. p values
highlighted in bold face fontwere those that approached signiﬁcance, while thosemarked






WT females Ammonia 33 (5) 48 (4) 0.02
Arg 119 (14) 118 (10) 0.9
Cys 12.4 (7.9) 27 (8) 0.2
Gln 639 (35) 587 (68) 0.5
Sarc 8.9 (5.7) 12.2 (8.1) 0.7
G93A3.6. Methionine Sulfoximine (MSO), an inhibitor of glutamine synthetase
affects the plasma amino acid proﬁle of SOD1G93A mice
Methionine sulfoximine (MSO), a mechanism-based inhibitor of
glutamine synthetase extends the survival of the SOD1G93A mouse and
is more effective in females than in males. Wild type and SOD1G93A
mice were treated once a week with i.p. injections of either saline or
20mg/kg MSO starting at 50 days of age. This dosage has been shown
to be well-tolerated by mice, even when injected three times per
week [23] and is the dosage and timing we have used in our previous
studies [11,16,26]. 50 days was chosen as the starting point in order
to treat mice that were adults but presymptomatic. Table 6 shows
the plasma metabolites that differ in SOD1G93A mice after MSO treat-
ment. SOD1G93A mice treated with MSO show several changes:
phosphoethanolamine, α-aminoadipic acid, and ornithine levels
increase, while average sarcosine levels decrease. Asparagine, alanine,
arginine, and cysteine levels increase signiﬁcantly with MSO treatment,
while – not surprisingly – average glutamine levels decrease. Cysteine,
which is undetectable in saline-treated SOD1G93A mice, becomes
detectable after MSO treatment.Table 6
The effects of MSO treatment on average plasma metabolite levels in SOD1G93A mice. All
values are expressed as averages in μmol/L (SEM). For the plasma ammonia analysis
n = 34 mice/treatment group. For the remainder of the plasma metabolites n = 14 for







Ammonia 35 (3) 52 (5) 0.00
AAAA 10.6 (1.4) 17.6 (1.7) 0.00
Ala 594 (33) 743 (55) 0.00
Arg 101 (8) 137 (11) 0.01
Asn 43 (3) 57 (4) 0.01
Cys 0.0 (0.0) 5.3 (2.1) 0.03
Gln 594 (24) 449 (29) 0.00
Lys 280 (19) 358 (25) 0.02
Orn 74 (6) 96 (8) 0.02
Pea 0(0) 4.7 (1.2) 0.01
Sarc 32 (5) 18.3 (3.4) 0.033.7. The effect of MSO on amino acid levels is gender speciﬁc
Since MSO extends the survival of the SOD1G93A mouse in a gender
speciﬁcmanner,with females living longer thanmales,wemight expect
that it would also affect plasma amino acid proﬁles in a gender-
dependent fashion [11,16].
The plasma metabolites that are altered by MSO can be seen in
Table 6 and the gender speciﬁc changes in Table 7. MSO treatment has
a minimal effect on wild type female mice, only slightly elevating
plasma ammonia, but does affect SOD1G93A female mice, elevating
plasma ammonia and cysteine levels and signiﬁcantly decreasing
plasma levels of glutamine and sarcosine.
Male wild type mice treated with MSO show signiﬁcant elevations
in average plasma levels of ammonia, phosphoserine, phospho-
ethanolamine, glutamate, ornithine, and lysine. Male SOD1G93A mice
treated with MSO also show moderate elevations in average plasma
ammonia levels, and much like wild type males, show elevations in
average levels of phosphoethanolamine. These mice also show
signiﬁcant increases in average plasma levels of α-aminoadipic acid,
alanine, and tryptophan, changes that are not observed in any other
group.
It is interesting to note that in 70-day old mice, SOD1G93A females
show elevated levels of plasma sarcosine when compared to their
wild-type counterparts (Table 3), and that whileMSO treatment lowers
plasma sarcosine levels in these mice, ovariectomized female SOD1G93A
mice have undetectable levels of sarcosine in their plasma (Table 5). As
discussed below, these differences point to an alteration ofmethylation/
demethylation reactions in the SOD1G93A mice.SOD1 Females Ammonia 33 (4) 53 (6) 0.01
Arg 115 (8) 152 (14) 0.04
Cys 0.0 (0.0) 3.6 (2.9) ND
Gln 647 (26) 465 (45) 0.005
Sarc 38 (5) 20 (5) 0.02
WT males Ammonia 22 (4) 34 (2) 0.02
AAAA 13.2 (2.3) 18.2 (4.7) 0.4
Ala 674 (28) 792 (102) 0.3
Cys 14.2 (8.3) 27 (7) 0.3
Glu 8.3 (3.8) 29 (6) 0.01
Lys 262 (9) 323 (21) 0.02
Orn 71 (11) 102 (7) 0.04
Pea 1.0 (1.0) 9.0 (3.1) 0.03
Phser 6.5 (1.1) 13.5 (2.1) 0.01
Trp 50 (5) 30 (12.6) 0.1
SOD1G93A males Ammonia 32 (5.2) 50 (7) 0.05
AAAA 10.1 (0.8) 16.8 (2.3) 0.02
Ala 521 (43) 710 (54) ND
Cys 0.0 (0.0) 7.0 (3.1) 0.02
Glu 11.1 (5.5) 23 (4) 0.1
Orn 73 (10) 97 (18) 0.09
Pea 0.6 (0.6) 5.7 (1.7) 0.02
Phser 6.6 (1.5) 7.9 (2.9) 0.7
Trp 43 (7) 66 (4) 0.01
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Progress in ameliorating the suffering of ALS patients has been
signiﬁcantly hindered by the lack of useful biomarkers for early disease
diagnosis and for monitoring the efﬁcacy of drug treatment. Many
biochemical, neurological, and radiological correlates of ALS have been
reported but none have proved to have the requisite sensitivity or
speciﬁcity.
The search for useful biomarkers has applied diverse methods:
transcriptional analysis, high sensitivity identiﬁcation of proteins and
metabolites by mass spectroscopy and high resolution NMR, and
diffusion tensor radiography [5,24]. The ideal biomarker would be
measured following a minimally invasive procedure that is inexpensive
and rapid to assay, and would use clinical protocols currently available
in all hospitals; sophisticated analytic tools, while valuable in iden-
tifying the underlying biochemical processes in ALS are less suitable in
clinical settings.
Amino acid analysis of blood plasma satisﬁes all these criteria, and
several studies have in fact shown abnormalities of plasma amino acid
proﬁles in ALS patients, but different amino acids have been identiﬁed
as abnormal in different studies. Iwasaki and colleagues found elevated
levels of aspartate, glutamate, and glycine; Perry and coworkers
found increased glutamate, glutamine, and cysteine, while threonine,
methionine, phenylalanine, and histidine decreased; Ilzecka and
colleagues found higher glutamine and serine, and lower tyrosine
valine, methionine, leucine and isoleucine [8,9,25]. More sophisticated
and larger metabolomic screens have also identiﬁed plasma amino
acids or their breakdown products that differ in ALS patients [4,26].
The failure to ﬁnd a consistent clinical amino acid proﬁle for ALS is
not surprising since the patient populations are highly heterogeneous,
both in their underlying genetics and in their disease stage. The use of
small patient populations and single instead of longitudinal analysis of
samples also decreased the statistical power of these studies. In
addition, the primary causes of ALS – still unknown –mightwell involve
differentmetabolic pathways, with all leading to a common endpoint of
muscle atrophy and respiratory failure [27–29].
In this report we reinvestigate the possibility of using plasma amino
acids as biomarkers for the disease in the SOD1G93Amousemodel of ALS.
Our studies take advantage of the synchronized disease progression and
genetic uniformity of the SOD1G93A model, and we have conﬁned our
analysis to ‘asymptomatic’ mice, trying to identify early biochemical
changes; however pathological changes in SOD1G93A mice have also
been observed 13 days before our ﬁrst plasma amino acid analysis at
50days [30]. Compared to our mouse model, the heterogenous disease
presentation in patients means that a metabolomic ‘snapshot’ at one
time point in a genetically diverse population is unlikely to reveal useful
biomarkers for disease.
We have addressed two questions: First, can we identify plasma
amino acid biomarkers using this model in which genotype and disease
stage is precisely deﬁned? Second, do the plasma amino acids proﬁles
provide information about the biochemical basis of ALS?
4.1. Plasma amino acid proﬁles in wild type and SOD1G93A mice
ALS affects not only motor neurons, but is a multi-organ disease
affecting liver and muscle, the major organs involved in amino acid
metabolism. In later stages of the disease where muscle wasting is
prominent, levels of amino acids reﬂecting muscle breakdown should
increase [7,31–33]. In addition, changes in the amino acid proﬁle
might be expected due to general acidosis in the SOD1G93A mouse [34].
Three changes in the amino acid proﬁle might be expected, each
reﬂecting a current hypothesis about ALS: mitochondrial dysfunction,
oxidative stress, and excitotoxicity. Mitochondrial dysfunction might
affect amino acid intermediates of the urea and TCA cycles; oxidative
stress may be reﬂected in changes in the methionine/cysteine/
glutathione pathway and the arginine/NO pathway; excitotoxiciy maybe reﬂected in levels of glutamate, glycine, aspartate, glutamine, and
serine.
We observed all three types of predicted changes, with signiﬁcant
changes in amino acids involved in the urea cycle, neuron excitation,
and methylation and the related transsulfuration pathway: cysteine,
methionine, glycine, sarcosine, phosphoserine, and phosphoetha-
nolamine. These amino acids participate in GSH synthesis, methylation
of DNA, RNA, and lipids, and lipid synthesis. The observed changes
suggest aberrant methylation, a condition that is seen not only in ALS
but also in other neurodegenerative diseases [35–38].
4.2. Alterations in mitochondrial processes and metabolites
In plasma from 50 day old mice, there are signiﬁcant differences
between SOD1G93A and wild type in metabolites associated with
mitochondrial processes. Ammonia levels are higher in the SOD1G93A
mice, and urea cycle intermediates arginine, ornithine, and citrulline,
are all lower. Glutamate, aspartate, and urea are lower in SOD1G93A
animals, and glutamine is higher. At 70 days, only the differences in
ammonia and aspartate persist. Both the 50 day differences and the
70 day differences indicate an effect of the SOD1G93A mutation and/or
the disease process on the ammonia-handling characteristics of
mitochondrial metabolism. Besides the potentially pathogenic effects
of altered metabolic pathways in mitochondria, ammonia itself is
extremely toxic and is normally maintained at very low levels. Elevated
ammonia might contribute to cell death properties seen in neuro-
degeneration. Ovariectomization of SOD1G93A females lowers levels of
glutamine synthetase activity in the brain and liver, lowers levels of
CPSI activity in the liver, and raises levels of glutaminase activity in
the brain. Reduced estrogen therefore is correlated to lowered activity
of two enzymes that incorporate ammonia into other molecules, and
increased activity of an ammonia producing enzyme.
4.3. Changes in oxidative metabolism as biomarkers in ALS
Cysteine and cystine play multiple biological roles, including
immune cell function, synthesis of glutathione (GSH), the major
antioxidant of the brain, and cell signaling through its Cys/CySS redox
ratio [39,40]. Cystine is exchanged for cellular glutamate through the
cystine/glutamate antiporter followed by its reduction to cysteine;
this exchange plays an important role in glutamateric signaling [41].
Our amino acid analysis does not detect cystine, homocysteine, or
glutathione.
Our measurements show that cysteine levels are extremely low in
SOD1G93A mice, with cysteine completely undetectable in all but one
SOD1G93A mouse (Table 1). Cysteine concentrations are so abnormal
that they alone can be used to distinguish between wild type and
SOD1G93A asymptomatic mice. A logistic regression using only cysteine
correctly classiﬁes 25 of 31 wild type mice (81%) and 26 of 27
SOD1G93A mice (96%); a ROC curve from this classiﬁcation has an area
of 0.9. Low cysteine is seen inmany disease states: HIV infection, cancer,
sepsis, and intestinal disorders [42,43]. These conditions are often
associated with low natural killer (NKT) activity and muscle wasting.
Cysteine concentrations are independent of gender and age, but are
increased byMSO treatment in SOD1G93Amice (p=0.04,Mann–Whitney
for 70 day old mice; p = 0.00 combining 50 and 70 day old mice).
Oxidative damage has been implicated in the progression of ALS, with
mutant SOD1G93A mice engineered to have defect in γ-glutamylcysteine
ligase (the ﬁrst and rate limiting enzyme in glutathione synthesis)
showing a 55% reduction in average lifespan [44]. Since cysteine is rate-
limiting, low cysteine may lead to reduced GSH synthesis and sensitivity
to ROS. When SOD1G93A expression is conﬁned to skeletal muscle ROS
increases and extensive muscle damage occurs. Motor neurons
expressing mutant SOD1G93A in cell culture also have lower GSH and
GSH levels in the brain of the SOD1G93A are also altered [11,32,45].
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The disease-related changes observed in these studies suggest
aberrant methylation, a condition that is seen not only in ALS but also
in other neurodegenerative diseases [35–38]. Defects inDNAmethylation
have been linked to neurodegenerative disease including ALS ([36,46,47].
In NSC34 cultured cells increases in the DNA methyltransferase enzyme
(Dnmt), Dnmt3a [13]causes neurodegeneration, and this enzyme is also
expressed in the motor cortex and spinal cord motor neurons of SALS
(Sporadic Amyotrophic Lateral Sclerosis) patients. In addition, SALS
patients show large scale changes in brain methylation patterns [38].
A possible biomarker for this pathway is homocysteine, a central
intermediate in the methylation pathway, which is elevated in ALS
patients [48].
We have found striking changes in metabolites in the linked
methylation and transsulfuration pathways in SOD1G93A mice. Serine,
phosphoserine, sarcosine, phosphoethanolamine, methionine, glycine,
cysteine, are metabolites in closely integrated metabolic pathways,
and all show changes in SOD1G93A mice. Brieﬂy, the methionine cycle
regenerates methionine from homocysteine in a vitamin B-12
dependent methylation with 5-methyltetrahydrofolate as the donor.
Methionine can then be converted to S-adenosylmethionine (SAM)
which is the primary donor for the methylation of DNA, RNA, and
proteins. After the transfer of the methyl group, SAM is recycled to
homocysteine. Alternatively, homocysteine can react with betaine to
form methionine and dimethylglycine, the later is then converted to
sarcosine (N-methylglycine). Sarcosine is rapidly degraded to glycine,
a precursor to both serine and ethanolamine. Homocysteine is also a
precursor of cysteine and hence glutathione, and these reactions
comprising the transsulfuration pathway. SAM can also methylate
phosphatidylethanolamine to phosphatidylcholine [49].
SOD1G93A mice show a remarkable elevation in sarcosine at 70days
of age (p = 0.00, d = 1.8, 0.8–2.7) (Tables 2A and 2B). Sarcosine
(N-methylglycine) is an intermediate in the choline-to-glycine pathway
and is metabolized to glycine, serine, and ethanolamine; it is also an
inhibitor of glycine transporter 1 [50]. Sarcosine in SOD1G93A mice is
elevated in both males and females at this age, and MSO reduces it in
both genders. Since elevations are not seen at 50 days, sarcosine is
potentially a biomarker of progression. In contrast to sarcosine, glycine
becomes lower in 70 day SOD1G93A mice (p= 0.00, d = 1.5, 0.6–2.4).
Sarcosine can be made from dimethylglycine in the homocysteine
to methionine reaction or directly from glycine by glycine-N-
methyltransferase; conversely sarcosine can be converted to glycine
by sarcosine dehydrogenase. These reactions are of importance to
neurological function and it has been postulated that they control the
important SAM/SAH ratio [51,52]. Sarcosine inhibits glycine transport
into astrocytes by blocking the Gly1T1 transporter, which would be
expected to activate the NMDA receptor by occluding the D-serine/
glycine site.
Phosphoserine concentrations are lower in SOD1G93A mice than in
wild type. Lowered phosphoserine has also been found in the CSF of
ALS patients [53]. Phosphoserine is converted to serine by phosphoserine
phosphatase. Alterations in phosphoserine phosphatase may play a role
in glutamate neurotoxicity in Alzheimer's disease, and phosphoserine is
elevated in ecstasy (MDMA) users [54,55]. Serine is synthesized from
glucose through 3-phosphoglycerate with this dephosphorylation as
the ﬁnal reaction. Serine may also be derived from glycine produced
from the degradation of proteins or phospholipids. D-serine, produced
from L-serine by L-serine racemase enhances glutamate toxicity in ALS
[56,57]. Enzymes involved in D/L serine metabolism have altered
transcription in asymptomatic SOD1G37R mice [58].
Phosphoethanolamine is present in high concentrations in the
brain and is a precursor to both acetylcholine and the high-energy
donor CDP-ethanolamine. Decreased levels of phosphoethanolamine
are found in Alzheimer's and Huntington's disease [59]. In our studies,phosphoethanolamine levels vary with genotype, gender, and age. We
measured decreases with age in both wild type and SOD1G93A mice,
but SOD1G93A mice have signiﬁcantly lower levels at both ages. Wild
type females have the same concentration at both ages, but males
have signiﬁcantly lower levels at 70 days of age. In contrast female
SOD1G93A mice show a large decrease with age.
4.5. Effects of age and gender on plasma amino acids
The results reported here imply that to be useful in ALS clinical
practice, amino acid proﬁles must control for gender and disease
stage. Both wild type and SOD1G93A mice exhibited signiﬁcant changes
in plasma amino acid composition between 50 and 70 days of age.
While it may seem surprising that we found amino acid changes
between the seemingly short, 50-70 day time span in wild type mice,
in humans this is roughly equivalent to early human childhood where
children from 3 months to 4 years of age also show age and gender
related changes in metabolites [60]. These changes then may be part
of the maturation process that differs between wild type and
SOD1G93A animals. We also found that ovariectomization changes the
plasma amino acid proﬁle and alters the levels of brain and liver
glutamine synthetase, liver glutaminase, and liver CPSI of SOD1G93A
mice. CPSI is dependent upon gender in humans, and sarcosine, the
metabolite most strongly affected by ovariectomization, is also under
androgen control in humans. Estrogens have been postulated as being
protective in ALS [22,61,62].
4.6. Use of plasma amino acid proﬁles to identify the underlying
biochemical defects in ALS
Amino acid proﬁles reﬂect a complex interaction between diet,
genetics, pharmacological compartment kinetics, and metabolic states.
It is difﬁcult to identify the underlying biochemical defects from these
changing proﬁles because while we understand to some extent the
network of amino acid synthesis and degradation pathways and the
kinetic parameters (at least in vitro) of the enzymes involved we lack
information about the correlations of amino acid concentrations and
the exchange kinetics between the organ compartments involved in
amino acid metabolism. Indeed, the underlying metabolic defect(s)
may change over the course of the disease, as seen by the fact that our
SOD1G93A mice have distinctly different proﬁles at 50 and 70 days
(Table 3).
Nevertheless the changes we observe lend support to theories about
the role of mitochondria and oxidative stress in ALS, and in addition
suggests that the recent striking observation of a methylation defect in
ALS may be reﬂected in plasma amino acids and metabolites such as
sarcosine and thereby provide a practical method for following disease
progression in a clinical setting.
The appropriate statistical tools for approaching this task have been
developed primarily from research on transcription networks in the last
decade. These tools include both standard (principal component
analysis, partial least squares) and newermethods for network analysis
[5]. We have not applied these more sophisticated tools to our analysis
of amino acid proﬁles because it would require an analysis of many
hundred mice and would have little clinical relevance. The appropriate
next study would involve measuring plasma amino acids, over time in
ALS patients that had been grouped by disease stage, gender, and type
of ALS (e.g. sporadic, familial), compared to matched control groups.
4.7. Useful biomarkers for ALS
Themousemodel closely mimicsmany of the features of the human
disease. It seems likely that all ALS patients have both common
biochemical changes due to motor neuron death and muscle atrophy
and unique changes dependent upon the underlying genetic defect.
Our observation of cysteine as a biomarker for the SOD1G93A mouse
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possibly due to the mixed patient population studied and may be an
example of a change unique to the SOD1G93A allele.
Given the relatively small number of control mice (31 wild type vs
27 SOD1G93A) identifying the key amino acids in a logistic regression
model is difﬁcult. The large number of amino acids measured relative
to the mouse population studied means that a good statistical ﬁt
can be derived from many different combinations of amino acids.
However, aspartate, cysteine, and phosphoethanolamine are abnormal
in SOD1G93A mice at both 50 and 70 days of age. Using all three
metabolites allows the correct identiﬁcation of 80% (24/30) of wild
type and 96% (22/23) of SOD1G93A mice with a ROC of 0.92(SE =
0.04). Using only aspartate and phosphoethanolamine we identify the
same number of wild type mice correctly, but only 18/23 SOD1G93A
with ROC = 0.86(SE = 0.06). Therefore, those metabolites are useful
disease biomarkers in mice.
4.8. Usefulness of plasma amino acid analysis to study effects of drugs
Our studies on the effects of MSO suggest that plasma amino acid
analysis might be used to screen potentially useful ALS drugs. From our
previous measurements of grip strength and survival we know that
MSO affects both males and female SOD1G93A mice, but with a larger
positive effect on female survival [11,16]. At 70 days, the diagnostic
metabolites for the SOD1G93A mice are phosphoethanolamine, aspartate,
sarcosine, glycine, and cysteine (Table 3); we omit discussion of NH4+
since this is directly dependent upon glutamine synthetase. Of these
only aspartate is closely related to an amino acid pathway expected to
be inﬂuenced by MSO, which is a site-speciﬁc inhibitor of glutamine
synthetase. Nonetheless, MSO affects the level of phosphoethanolamine,
sarcosine, and cysteine (Table 6) in SOD1G93A mice, in all cases
signiﬁcantly changing the levels in the direction of the wild type values.
It has been shown that MSO also increases glycogen deposit in the brain
[63], a possible compensatory mechanism for reducing acidosis recently
observed in the SOD1G93Amouse [34]. Acidosis by itself canmodulate the
levels of brain and plasma amino acids [64,65]. When mice are treated
with MSO, phosphoethanolamine is increased in both wild type and
SOD1G93A mice, and sarcosine decreases but only in female mice.
Cysteine is not changed in wild type mice but levels become non-zero
in SOD1G93A mice; the statistical signiﬁcance is difﬁcult to calculate due
to the severely non-normal distribution. MSO has no effect on plasma
amino acids in wild type female mice. It is interesting to note that in
addition to inhibiting glutamine synthetase, MSO also has major effects
on levels of brain S-adenosylmethionine and methylation reactions,
consistent with the disturbances in methylation-related metabolites
that we have found [66–68].
Given these observations, even in the absence of any information of
MSO on disease progress, it is clear that MSO would be ﬂagged as a
potentially useful drug once the amino acid proﬁle of treated and
untreated SOD1G93A mice had been established and compared to
wild type mice. Similar analysis of the effects of drugs on plasma
metabolites might therefore be useful in identifying therapeutically
useful compounds.
4.9. Summary
The SOD1G93A mutation that causes an ALS-like disease in mice
produces signiﬁcant changes in plasma amino acids and other
metabolites, most signiﬁcantly those concentrated in the methylation
and related pathways affecting levels of cysteine, serine, phosphoserine,
taurine, phosphoethanolamine, sarcosine, glycine, methionine, and
aspartate. The fact that these changes are observed in presymptomatic
animals suggests that the analysis of plasma metabolites might be
useful in monitoring the progression of ALS in humans, if similar
amino acid analyses can be done onwell-deﬁned groups of ALS patients
over time.Acknowledgements
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